Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery

The central nervous system (CNS) is the major area that is affected by aging. Alzheimer’s disease (AD), Parkinson’s disease (PD), brain cancer, and stroke are the CNS diseases that will cost trillions of dollars for their treatment. Achievement of appropriate blood–brain barrier (BBB) penetration is often considered a significant hurdle in the CNS drug discovery process. On the other hand, BBB penetration may be a liability for many of the non-CNS drug targets, and a clear understanding of the physicochemical and structural differences between CNS and non-CNS drugs may assist both research areas. Because of the numerous and challenging issues in CNS drug discovery and the low success rates, pharmaceutical companies are beginning to deprioritize their drug discovery efforts in the CNS arena. Prompted by these challenges and to aid in the design of high-quality, efficacious CNS compounds, we analyzed the physicochemical property and the chemical structural profiles of 317 CNS and 626 non-CNS oral drugs. The conclusions derived provide an ideal property profile for lead selection and the property modification strategy during the lead optimization process. A list of substructural units that may be useful for CNS drug design was also provided here. A classification tree was also developed to differentiate between CNS drugs and non-CNS oral drugs. The combined analysis provided the following guidelines for designing high-quality CNS drugs: (i) topological molecular polar surface area of <76 Å2 (25–60 Å2), (ii) at least one (one or two, including one aliphatic amine) nitrogen, (iii) fewer than seven (two to four) linear chains outside of rings, (iv) fewer than three (zero or one) polar hydrogen atoms, (v) volume of 740–970 Å3, (vi) solvent accessible surface area of 460–580 Å2, and (vii) positive QikProp parameter CNS. The ranges within parentheses may be used during lead optimization. One violation to this proposed profile may be acceptable. The chemoinformatics approaches for graphically analyzing multiple properties efficiently are presented.

[1]  Michelle A. Schmidt,et al.  To Market, To Market—2009 , 2010 .

[2]  Tudor I. Oprea,et al.  Model-Free Drug-Likeness from Fragments , 2010, J. Chem. Inf. Model..

[3]  Kristen B. LaBonte,et al.  Computational approaches to the prediction of blood-brain barrier permeability: A comparative analysis of central nervous system drugs versus secretase inhibitors for Alzheimer's disease. , 2006, Current opinion in drug discovery & development.

[4]  M. Leider.  Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .

[5]  U. Norinder,et al.  Computational approaches to the prediction of the blood-brain distribution. , 2002, Advanced drug delivery reviews.

[6]  M. Abraham,et al.  On the partition of ampholytes: application to blood-brain distribution. , 1997, Journal of pharmaceutical sciences.

[7]  P. Verhoest,et al.  Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. , 2010, ACS chemical neuroscience.

[8]  A. J. Hopfinger,et al.  Predicting Blood–Brain Barrier Partitioning of Organic Molecules Using Membrane–Interaction QSAR Analysis , 2002, Pharmaceutical Research.

[9]  Stephen G. Aller.  Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding , 2010 .

[10]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[11]  H. Pajouhesh,et al.  Medicinal chemical properties of successful central nervous system drugs , 2005, NeuroRX.

[12]  Elazer R. Edelman,et al.  Adv. Drug Delivery Rev. , 1997 .

[13]  Stephen A. Wring,et al.  Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs , 2002, Journal of Pharmacology and Experimental Therapeutics.

[14]  Denis M. Bayada,et al.  Polar Molecular Surface as a Dominating Determinant for Oral Absorption and Brain Penetration of Drugs , 1999, Pharmaceutical Research.

[15]  Dora Brites,et al.  Looking at the blood–brain barrier: Molecular anatomy and possible investigation approaches , 2010, Brain Research Reviews.

[16]  Roger L. Black,et al.  Goodman and Gilman's The Pharmacological Basis of Therapeutics , 1991 .

[17]  P. Verhoest,et al.  Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. , 2010, ACS chemical neuroscience.

[18]  J. Schellens,et al.  Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. , 2006, Trends in pharmacological sciences.

[19]  Arup K. Ghose,et al.  Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery. , 2008, Journal of medicinal chemistry.

[20]  Francesco Berardi,et al.  Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: pharmaceutical, biological, and diagnostic potentials. , 2010, Journal of medicinal chemistry.

[21]  P. Verhoest,et al.  Strategies to optimize the brain availability of central nervous system drug candidates , 2011, Expert opinion on drug discovery.

[22]  D. Manallack.  The pKa Distribution of Drugs: Application to Drug Discovery , 2007, Perspectives in medicinal chemistry.

[23]  Paul D Leeson,et al.  Time-related differences in the physical property profiles of oral drugs. , 2004, Journal of medicinal chemistry.

[24]  D. E. Clark,et al.  Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. , 1999, Journal of pharmaceutical sciences.

[25]  W. Pardridge,et al.  Blood-brain barrier delivery. , 2007, Drug discovery today.

[26]  Terry R Stouch,et al.  Progress in understanding the structure-activity relationships of P-glycoprotein. , 2002, Advanced drug delivery reviews.

[27]  S. Hitchcock,et al.  Structure-brain exposure relationships. , 2006, Journal of medicinal chemistry.

[28]  J R Chretien,et al.  Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. , 1998, Journal of drug targeting.

[29]  D. E. Clark.  Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. , 1999, Journal of pharmaceutical sciences.

[30]  Harpreet S. Chadha,et al.  Hydrogen bonding. 33. Factors that influence the distribution of solutes between blood and brain. , 1994, Journal of pharmaceutical sciences.

[31]  T. Tsuruo,et al.  Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. , 1981, Cancer research.

[32]  R. Fogel,et al.  Forecasting the Cost of U.S. Health Care in 2040 , 2008 .

[33]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[34]  W. Pardridge,et al.  Drug and Gene Delivery to the Brain The Vascular Route , 2002, Neuron.

[35]  Harpreet S. Chadha,et al.  Hydrogen-bonding. Part 36. Determination of blood brain distribution using octanol-water partition coefficients. , 1995, Drug design and discovery.

[36]  W. Stigelman,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .

[37]  A. Ghose,et al.  A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. , 1999, Journal of combinatorial chemistry.

[38]  D. E. Clark.  Computational Prediction of Blood-brain Barrier Permeation , 2005 .

[39]  Marc Adenot,et al.  Blood-Brain Barrier Permeation Models: Discriminating between Potential CNS and Non-CNS Drugs Including P-Glycoprotein Substrates , 2004, J. Chem. Inf. Model..

[40]  D. Manallack,et al.  Drug Targeting of α-Synuclein Oligomerization in Synucleinopathies , 2007 .

[41]  D. E. Clark.  In silico prediction of blood-brain barrier permeation. , 2003, Drug discovery today.

[42]  Ulrich Friedemann,et al.  BLOOD-BRAIN BARRIER , 1942 .

[43]  Gordon M. Crippen,et al.  Predicting pKa , 2009, J. Chem. Inf. Model..

[44]  Henry Brem,et al.  Drug Delivery to the Central Nervous System: A Review , 1992 .

[45]  Marc Adenot,et al.  Blood‐Brain Barrier Permeation Models: Discriminating Between Potential CNS and Non‐CNS Drugs Including P‐Glycoprotein Substrates. , 2004 .

[46]  A. Ghose,et al.  Knowledge-based chemoinformatic approaches to drug discovery. , 2006, Drug discovery today.

[47]  A. Leo,et al.  Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. , 1987, Journal of pharmaceutical sciences.